Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Forschner

Showing results (71-80 of 157) with videos related to

Pageof 16
Sort By:
Oncotarget|April 19, 2017
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspJessica C Hassel, Carola Berking, Andrea Forschner, et al.
JMIR Cancer|June 14, 2022
Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening AnalysisJyoti Chauhan, Sathyaraj Aasaithambi, Iván Márquez-Rodas, et al.
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
BMJ Open|December 21, 2016
Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Christine Fink, Maja Hofmann, Agata Jagoda, et al.
International Journal of Cancer|November 11, 2025
Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021Jona Laukhuf, Lisa Wiens, Gerd Grözinger, et al.
Cancers|April 26, 2020
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV MelanomaTeresa Amaral, Olivia Seeber, Edgar Mersi, et al.
Diagnostics (Basel, Switzerland)|September 23, 2022
Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI DataThomas Küstner, Jonas Vogel, Tobias Hepp, et al.
Pageof 16

Showing results (71-80 of 157) with videos related to

Sort By:
Pageof 16
Oncotarget|April 19, 2017
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Journal of the American Academy of Dermatology|April 25, 2009
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patientsFriedegund Meier, Emmanuella Guenova, Stephan Clasen, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspJessica C Hassel, Carola Berking, Andrea Forschner, et al.
JMIR Cancer|June 14, 2022
Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening AnalysisJyoti Chauhan, Sathyaraj Aasaithambi, Iván Márquez-Rodas, et al.
Plos One|May 3, 2013
Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosisBenjamin Weide, Christine Faller, Petra Büttner, et al.
BMJ Open|December 21, 2016
Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Christine Fink, Maja Hofmann, Agata Jagoda, et al.
International Journal of Cancer|November 11, 2025
Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021Jona Laukhuf, Lisa Wiens, Gerd Grözinger, et al.
Cancers|April 26, 2020
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV MelanomaTeresa Amaral, Olivia Seeber, Edgar Mersi, et al.
Diagnostics (Basel, Switzerland)|September 23, 2022
Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI DataThomas Küstner, Jonas Vogel, Tobias Hepp, et al.
Pageof 16